Middle East and Africa Patient Controlled Injectors Market Growth and Forecast by 2027

The Middle East & Africa patient controlled injectors market is expected to reach US$ 371.53 million by 2027 from US$ 157.85 million in 2019; it is estimated to grow at a CAGR of 11.4% from 2020 to 2027.

The patient-controlled injectors are the newest invention in the administration of injections. There are high-unmet needs of people/ HCPs or patients requiring the patient-controlled injectors as it has greater ease and comfort than any other auto-injectors. These are ergonomically developed, and design patient-controlled injectors can help optimize self-care, making it easy for patients to hold the system and administer the dosages at just one press.

Patient controlled Injectors are subcutaneous drug delivery systems that adhere to the body and administer larger volumes (more than 2 mL) of a drug over an extended period. With the use of patient-controlled injectors, dosing errors, microbial contamination risks, and needle stick injuries can be avoided that are caused during parenteral drug administration using injections. In the last few years, the pharmaceutical industry has witnessed the introduction of several innovative interventions for the treatment of various chronic diseases. However, the majority of the available treatment options require parenteral drug administration, frequent dosing, and repeated hospital visits. Therefore, patient controlled injectors are preferred for the treatment of chronic diseases where long-term treatment is necessary. Chronic diseases, such as blood disorder, autoimmune disorders, and various types of cancer, are the leading causes of death and disability.

Cardiovascular diseases (CVDs) are a significant cause of mortality owing to the hectic lifestyle. For Instance, in 2018, Ministry of Health and Prevention report (MHP) has revealed that CVD is a leading cause of mortality in the UAE. Of CVD deaths, 22% were attributable to acute myocardial infarction (AMI), 16% to cerebrovascular disease, 6% to ischaemic heart disease and 5% to hypertension. Many biologics are commercially available for the treatment, but the conventional drug delivery methods are unable to provide accurate dosage. This augments the use of patient controlled injector drug delivery systems that provide targeted drug delivery and prolonged drug residence to the affected areas of the cardiovascular system. Hence, the adoption of patient controlled injectors is likely to increase, thereby propelling the Patient Controlled Injectors market growth.

The COVID-19 has shown substantial effects in Middle East and Africa. The pandemic has affected the research and development activities in these countries. The economic uncertainties and ongoing conflicts are worsening the condition in the region. These factors are expected to negatively impact the growth of the cell line development serum market in the region. However, the recent pandemic is causing turbulence to the economies of the Middle East region. A sudden drop in domestic and external demand for goods and products especially medical devices specially for alternative treatments other than COVID-19, production due to labour shortage are some of the major impacts observed in the region. Additionally, tightened financial condition is also decreasing the overall economic activities in the region. This uncertainty with normal delays often associated with regulatory approvals in low- and middle-income countries is hindering the growth of the market.

Rest of Middle East & Africa Patient Controlled Injectors Market, Revenue and Forecast to 2027 (US$ Mn)

MIDDLE EAST & AFRICA PATIENT CONTROLLED INJECTORS MARKET SEGMENTATION

By Product

• Electronic Wearable Injector
• Mechanical Wearable Injector
• Infusion Pumps

By Application

• Cancer Treatment
• Auto-immune Treatment
• Blood Disorders Treatment
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Mail Order Pharmacies

By Country

• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Company Profiles

• Johnson and Johnson Services, Inc.
• Sensile Medical AG (Gerresheimer AG)
• F. HOFFMANN-LA ROCHE LTD
• Ypsomed AG
• Westbourne Medical Limited

Middle East and Africa Patient Controlled Injectors Report Scope